Antennova, a Delaware corporation, is a clinical-stage biotech company specialized in developing innovative therapeutics that re-educate the tumor microenvironment, enhancing the effectiveness of standard therapies and reversing checkpoint inhibitor (CPI) resistance, as well as targeting “cold tumors” that are not responsive to the current CPI therapies. Antennova has achieved significant milestones which include advancing and developing 4 clinical stage programs: ATN-031: anti-CD24 monoclonal antibody; ATN-037: CD73 small molecule inhibitor; ATN-022: Claudin 18.2 ADC; and ATN-101: anti-PD-L1/4-1BB bispecific antibody. The U.S. Food and Drug Administration (FDA) awarded an Orphan Drug Designation to ATN-101, for pancreatic cancer; and to ATN-022, for gastric and pancreatic cancers.
Company Details
- Founded
- -
- Address
- 3805 Old Easton Rd,
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://www.antennova.com/
- Keywords
- Cold Spring Harbor.
- HQ
- Doylestown, Pennsylvania
Antennova Questions
Antennova's website is https://www.antennova.com/
Antennova's LinkedIn profile is https://www.linkedin.com/company/antennova
Antennova's industry is
Biotechnology Research
Antennova's top competitors are
Laurel Hollow Capital,
Genecraft Inc.,
Curevac,
Morphosys,
Medigene Ag,
Antengene,
Opsidio, Llc,
Score Pharma, Inc.,
Evolution Biologyx,
Immatics.
Antennova's categories are Biotechnology Research
Antennova's founding year is 2024
